MorphoSys shares plunge after partner Roche says Alzheimer’s drug trials didn’t meet goals

German-listed shares of MorphoSys lost a third of their value on Monday after its partner Roche said an Alzheimer drug trial failed. Roche slumped 4% in Zurich as the company said Phase 3 studies evaluating gantenerumab in people with mild cognitive impairment (MCI) due to Alzheimer’s and mild Alzheimer’s dementia did not meet their primary endpoint of slowing clinical decline.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.